Australia: Omnibus claims and the doctrine of equivalents

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Australia: Omnibus claims and the doctrine of equivalents

For many years, Australia has allowed omnibus claims, which take the form of "an apparatus substantially as hereinbefore described…". They have been utilised as a last line of defence for patentees when suing defendants.

Unfortunately, Australia does not have a strong doctrine of equivalence, found for example, in US jurisprudence. Hence, we have tended towards a literal infringement of claims.

Any hope that the omnibus claim would assist in finding non-literal infringement of patent applications has recently been dashed by our Full Federal Court in GlaxoSmithKline Australia Pty Ltd v Reckitt Benckiser Healthcare (UK) Ltd [2016] FCAFC 90.

The subject matter of the case dealt with a spill-free syringe dispensing system, which dominated the consumer market. The defendants had invented around the main claim and had developed an alternate syringe that the trial judge found had "exactly the same function". Unfortunately, for the patentee, the defendant's modifications meant that there was no literal infringement of the main claims.

The trial judge held that the omnibus claim could be utilised in a doctrine of equivalence sense to cover the "substance" of the invention. The Full Court overruled the trial judge, and, as a result, severely curtailed the operation of omnibus claims. The Court noted the overriding requirement for the omnibus claim to not extend beyond what was covered by the claims.

As a consequence, omnibus claims (which have recently also been curtailed by our Patents Act), are significantly reduced in effectiveness. Also, our courts appear to be moving towards a literal infringement position of patent claims which will be of great concern to patentees.

treloar.jpg

Peter Treloar


Shelston IPLevel 21, 60 Margaret StreetSydney NSW 2000, AustraliaTel: +61 2 9777 1111Fax: +61 2 9241 4666email@shelstonip.comwww.shelstonip.com

more from across site and SHARED ros bottom lb

More from across our site

In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Six hires across the IP spectrum reflect Orrick’s efforts to better serve tech clients across the IP lifecycle
David Stone, partner at White & Case, argues that the government’s planned reforms will modernise and futureproof UK design law, but leave two of the thorniest problems unresolved
Max Scott will join the firm’s IP transactions group in California, becoming the latest Weil IP partner to secure their future
Yonatan Drori, attorney at Drori-Stav IP in Israel, explains why foreign counsel must treat Israel’s patent disclosure requirements as an ongoing obligation, rather than a one-off formality
From Japan to Southeast Asia, domestic and regional firms picked up some of the biggest prizes, while key foreign players maintained momentum
Earlier this month, Managing IP had exclusively reported that the French arm of Taylor Wessing was minded to pull out of the deal
Our latest podcast examines how Weil’s IP practice evolved, where its practitioners could (and will) go next, and which firms and markets stand to benefit from the redistribution of talent
Gift this article